Bio-K Plus, a pioneer and probiotic specialist since 1994, has announced that a recently published study adds to the ever-growing body of evidence confirming the effectiveness of Bio-K+’s probiotic form formulation in reducing the risk of Clostridioides difficile infection (CDI).
The independent research was done at the Regional Hospital Center of Lanaudiere, Quebec, Canada, by Dr. Pierre-Jean Maziade, MD, and was recently published in Clinical Infectious Diseases, a prestigious medical journal. The addition of Bio-K+ to a pharmacy-driven protocol tied to antibiotic prescriptions caused a significant decrease of 39% hospital CDI cases over an 18-months compared to the preceding 12-months observation period during which Bio-K+ was not co-administered with antibiotics.
“We owe the study’s success to the high prevalence of Bio-K+’s prescription in hospitalized antibiotic users. Thus, 70% of eligible patients took Bio-K+ during the intervention period,” said Dr. Pierre-Jean Maziade.
“Our new clinical study is an addition to the many clinical studies performed in various North American hospitals over the past two decades. By combining medical-grade probiotic formulations with standard preventative measures, it is possible to reduce the incidence of C. difficile infections further”, explained Mathieu Millette, Ph.D. Scientific Director of Bio-K Plus.
In the research, Bio-K+ probiotic formulation was given to participants, some of whom were at increased risk of CDI. The results were consistent with those of previously conducted clinical and observational studies. C. difficile is responsible for about half a million infections, tens of thousands of deaths, and billions of dollars in additional healthcare costs each year in the USA.
Health Canada approves Bio-K+ as a Natural Health Product to help reduce the risk of developing C. difficile associated diarrhea in hospitalized patients. The patented and exclusive probiotic formulation results from a unique fermentation and manufacturing process that combines strains of L. acidophilus and L. casei. More than 20 years of clinical research supports its effectiveness, including multiple randomized, placebo-controlled studies and observational studies. It is also reinforced by over 100,000 documented patient cases without serious adverse effects.
